The Medicines and Healthcare products Regulatory Agency published its UK position on microbiome-based medicinal products on 18 August 2026. The document explains the licensing route and gives developers a clearer basis for working within the existing medicines framework.
The position is intended to support consistent regulatory decisions while maintaining the evidence, quality and safety standards expected for medicinal products in the UK.